Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 564-573 , May 2009

Costs of Hematopoietic Cell Transplantation: Comparison of Umbilical Cord Blood and Matched Related Donor Transplantation and the Impact of Posttransplant Complications

Received 16 December 2008 ,Accepted 14 January 2009.

References 

  1. Bennett C, Waters T, Stinson T, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24:555–560
  2. Cordonnier C, Maury S, Esperou H, et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant. 2005;36:649–654
  3. Esperou H, Brunot A, Roudot-Thoraval F, et al. Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective, multicenter, French study. Transplantation. 2004;77:1854–1858
  4. Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 1998;92:4047–4052
  5. Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000;18:64–71
  6. Lee SJ, Weller E, Alyea EP, Ritz J, Soiffer RJ. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood. 1998;92:2725–2729
  7. Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008;14:197–207
  8. Saito AM, Zahrieh D, Cutler C, et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007;40:209–217
  9. van Agthoven M, Groot MT, Verdonck LF, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant. 2002;30:243–251
  10. Stinson TJ, Adams JR, Bishop MR, Kruse S, Tarantolo S, Bennet CL. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2000;26:663–666
  11. Brunstein CG, Wagner JE. Cord blood transplantation for adults. Vox Sang. 2006;91:195–205
  12. Majhail NS, Brunstein CG, Wagner JE. Double umbilical cord blood transplantation. Curr Opin Immunol. 2006;18:571–575
  13. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110:3064–3070
  14. Majhail NS, Brunstein CG, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008;14:282–289
  15. Majhail NS, Weisdorf DJ, Wagner JE, Defor TE, Brunstein CG, Burns LJ. Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood. 2006;107:3804–3807
  16. Tomblyn M, Brunstein C, Burns LJ, et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:538–545
  17. Arora M, Nagaraj S, Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant. 2007;13:1145–1152
  18. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood. 2008;111:446–452
  19. Alyea EP, Kim HT, Ho V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006;12:1047–1055

 Financial disclosure: See Acknowledgments on page 572.

PII: S1083-8791(09)00054-8

doi: 10.1016/j.bbmt.2009.01.011

Biology of Blood and Marrow Transplantation
Volume 15, Issue 5 , Pages 564-573 , May 2009

Article Tools

* Image Usage & Resolution